Please login to the form below

Not currently logged in

Shire pitching at adult ADHD product launch in 2017

Will have to first trial formulation in children to appease FDA

Shire BasingstokeThe FDA has agreed a regulatory route for Shire's attention deficit hyperactivity disorder (ADHD) product for adults, potentially opening up a lucrative new market for the company's franchise.

Most cases of ADHD are diagnosed in children, and the prevailing wisdom has been that in most cases symptoms resolve as patients reach maturity. However, the adult form of the disorder is also remarkably common, with an estimated prevalence of up to 5%, and is considered to be the most severe long-term outcome of this neurodevelopmental disorder.

Shire wants to develop a drug called SHP465 (triple-bead mixed amphetamine salts) for adult ADHD, but to satisfy the FDA will have to first carry out a trial of the formulation in children, as was first revealed by the company last October.

The company had initially hoped to launch the product later this year, but the new regulatory route means that a timeframe of 2017 is more likely. The first patient is due to be enrolled into the paediatric trial in August.

"Adult patients with ADHD represent the fastest growing segment of the overall ADHD patient population," said Shire in a statement.

Breaking into the adult ADHD - as well as a sideways move into binge-eating disorder with paediatric ADHD therapy Vyvanse (lisdexamfetamine) - could eventually double sales of Shire's psychiatric portfolio by 2020, according to chief executive Flemming Ornskov. 

Last year, the company's psychiatric drugs brought in around $2.2bn in sales and royalties, a little over a third of its total annual revenues of $6bn.

Adults already receive treatment for ADHD off-label using drugs such as Adderall and Adderall XR - both also based on mixed amphetamine salts - but it is though that a sizeable proportion use the long- and short-acting form sequentially in order to control symptoms throughout the day. 

SHP465 will provide 16 hours cover from a single tablet, extending from the morning into the evening, according to Shire, which also expects the new formulation to claim three years' additional market exclusivity in the US, extending its patent protection out to 2029.

Article by
Phil Taylor

8th April 2015

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

Waking the sleeping giant
The lights are coming on for healthcare delivery in Africa...
How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...